About

Bacterial and fungal respiratory infections are the main causes of  mortality in patients with cystic fibrosis.  Inhaled antibiotics play a pivotal role in managing these infections as the drugs are delivered directly to the lungs.

Despite these advancements, much of the bacteria that cause lung infections in cystic fibrosis patients  has grown resistant to traditional antibiotics, rendering most currently available antimicrobials useless and ineffective. Furthermore, many cystic fibrosis patients develop resistant infections  and mixed bacterial-fungal infections, both of which respond poorly to antibiotc therapy. Thus, there is a critical need for the development of new broad-spectrum antimicrobials that can be effectively used to treat resistant bacteria and fungi in cystic fibrosis  patients.

TGV-inhalonix has developed a breakthrough novel drug candidate to treat these chronic and often fatal infections. Recently granted Orphan Drug Designation by the U.S. Food and Drug Administration, its candidate, Mul-1867, is the first inhaled antimicrobial being developed against multidrug-resistant bacteria and fungi in cystic fibrosis patients.